1. Introduction {#s0005}
===============

Current guidelines recommend first medical contact (FMC) to device time of ≤90 min in the treatment of ST elevation myocardial infarction (STEMI) \[[@bb0005]\]. These guidelines underscore the importance of total ischemic time (time of vessel occlusion and symptom onset to the re-establishment of antegrade blood flow) and pre-hospital initiatives aimed to decrease it. Despite continued improvements in STEMI system-based care, total ischemic time remains unacceptably long in patients who are slow to recognize symptoms and seek medical attention. Prior studies assessing predictors of presentation delay in STEMI primarily focus on delays of \<6 h \[[@bb0010], [@bb0015], [@bb0020]\]. However, the 12-hour mark after symptom onset remains relevant because it is the accepted timepoint used in decision-making regarding candidacy for reperfusion therapy \[[@bb0005]\]. The aim of this study was to determine predictors of very late (≥12 h) presentation of STEMI and to assess long-term mortality in this patient population.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the University of Virginia investigational review board. Due to the retrospective nature of the study protocol, the requirement for written informed consent from each patient was waived. We retrospectively examined consecutive patients admitted with STEMI to the University of Virginia using the ACTION Registry™ from January 2011 to December 2016. STEMI was defined by electrocardiogram (ECG) criteria as new ST segment elevation at the J-point in at least two contiguous leads of ≥0.2 mm in men or ≥1.5 mm in women in leads V~2~-V~3~ and/or ≥1 mm in other leads \[[@bb0005]\]. Reasons for exclusion included: unresponsive or cardiac arrest at FMC, a diagnosis other than STEMI, and undocumented symptom onset time or symptom description.

2.2. Data collection {#s0020}
--------------------

Demographics, co-morbidities, presenting symptom (presence or absence of chest pain), time of symptom onset, time of FMC, vital signs at FMC, laboratory and echocardiographic data, coronary angiographic data, in-hospital outcomes, and long-term all-cause mortality were collected. In-hospital outcomes included acute heart failure, cardiogenic shock, cardiac arrest, stroke, and death. Time of symptom onset to FMC was calculated for each patient and categorized as \<12 h or ≥12 h.

2.3. Statistical analysis {#s0025}
-------------------------

Continuous variables are displayed as medians with interquartile ranges and compared with Wilcoxon Rank Sum test. Categorical variables are displayed as absolute values with percentages of the total and compared using Chi-Square or Fisher\'s Exact test. Statistical analysis was 2-tailed and p-values of \<0.05 were considered to be statistically significant. Based on the two-group Wilcoxon Rank Sum or Chi-Square tests, clinically relevant differences between the two groups were evaluated with univariable logistic regression models. A stepwise, multivariable logistic regression was performed using a p-value \< 0.2 to enter the model and a p-value of \<0.05 to remain in the model. Odds ratios and 95% confidence intervals (CI) were calculated. Long-term survival curves using Kaplan-Meier methodology were constructed and compared using the log-rank test. Hazard ratios with 95% CI were calculated using Cox proportional hazards regression. Mortality at 1 year was compared using Chi-Square. Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC).

3. Results {#s0030}
==========

3.1. Patient characteristics {#s0035}
----------------------------

A total of 559 patients with STEMI between 2011 and 2016 were available in the ACTION Registry™ in our institution. A total of 145 were excluded (34 were unresponsive at FMC, 35 had a diagnosis other than STEMI, and 76 did not have their symptom onset or description documented). The analysis was based on the remaining 414 patients, of whom 365 (88%) had symptom onset to FMC time of \<12 h, and 49 (12%) with symptom onset to FMC time of ≥12 h.

Nearly half of the very late presenters were women compared to 28% of patients presenting \<12 h, and those who presented very late had higher rates of diabetes and prior coronary artery bypass surgery ([Table 1](#t0005){ref-type="table"}). At FMC, very late presenters had higher heart rates and lower systolic blood pressures, and were less likely to be transported by emergency medical services ([Table 2](#t0010){ref-type="table"}). Those who presented very late were less likely to report chest pain as their presenting symptom, and had lower left ventricular ejection fractions on the initial echocardiogram.Table 1Baseline patient characteristics.Table 1Variable\<12 h≥12 hp-ValueN = 365N = 49Female sex101 (28%)23 (47%)0.006Age (years)58 (50,68)61 (54,71)0.095Race0.380 White306 (84%)37 (76%) African American42 (12%)7 (14%) Hispanic8 (2%)2 (4%) Asian9 (2%)3 (6%)Body mass index (kg/m^2^)29 (26,34)29 (25,33)0.535Family history of coronary artery disease203 (56%)26 (53%)0.738Tobacco use256 (70%)34 (69%)0.914Hypertension231 (63%)31 (63%)0.998Hyperlipidemia169 (46%)26 (53%)0.373Diabetes mellitus91 (25%)27 (55%)\<0.0001Chronic obstructive pulmonary disease33 (9%)5 (10%)0.791Prior coronary artery disease102 (28%)12 (24%)0.611Prior myocardial infarction82 (22%)7 (14%)0.191Prior percutaneous coronary intervention79 (22%)7 (14%)0.233Prior coronary artery bypass surgery9 (2%)5 (10%)0.005Prior congestive heart failure22 (6%)6 (12%)0.104End stage renal disease on dialysis6 (2%)0 (0%)1.000Prior stroke22 (6%)5 (10%)0.348Peripheral arterial disease34 (9%)3 (6%)0.600Medications Aspirin123 (34%)15 (31%)0.716 P2Y12 inhibitor28 (8%)2 (4%)0.558 Anticoagulation16 (4%)3 (6%)0.475 Beta-blocker97 (27%)14 (29%)0.712 Angiotensin converting enzyme inhibitor93 (25%)15 (31%)0.399 Statin118 (32%)20 (41%)0.202[^2]Table 2Clinical data at first medical contact and test results.Table 2Variable\<12 h≥12 hp-ValueN = 365N = 49Heart rate (beats per minute)77 (65,90)89 (74,106)0.001Systolic blood pressure (mmHg)143 (124,167)133 (110,157)0.018Acute congestive heart failure49 (13%)10 (20%)0.189Cardiogenic shock24 (7%)4 (8%)0.760Cardiac arrest21 (6%)3 (6%)1.000Transported by EMS (air and ground)245 (67%)22 (45%)0.005First medical contact to device (minutes)93 (74,113)104 (75,121)0.264Chest pain312 (85%)35 (71%)0.012 No chest pain53 (15%)14 (29%)Chest pain within past 30 days120 (33%)11 (22%)0.141Initial troponin (ng/mL)0.1 (0.0,0.8)11.9 (2.5,24.9)\<0.0001Peak troponin (ng/mL)43 (17,91)37 (13,113)0.600Initial creatinine (mg/dL)1.0 (0.8,1.1)1.0 (0.8,1.3)0.586Initial hemoglobin (g/dL)14 (13,15)13 (12.5,15)0.033Left ventricular ejection fraction (%)48 (38,58)43 (33,53)0.003[^3]

Very late presenters were less likely to be referred for coronary angiography or to undergo PCI ([Table 3](#t0015){ref-type="table"}). During the index hospitalization, they were also more likely to develop acute heart failure, have longer lengths of stay, were less likely to be discharged to home, and more likely to be discharged to a rehabilitation center. In multivariable analysis, diabetes, female sex, and absence of chest pain were strongly associated with late presentation (c-statistic = 0.70) ([Table 4](#t0020){ref-type="table"}).Table 3In-hospital outcomes and discharge status.Table 3Variable\<12 h≥12 hp-ValueN = 365N = 49Referred for coronary angiography360 (99%)46 (94%)0.023Percutaneous intervention346 (94%)37 (76%)\<0.0001 Right coronary artery170 (49%)20 (54%)0.259 Left anterior descending123 (36%)9 (24%) Left circumflex45 (13%)8 (22%) Other[a](#tf0005){ref-type="table-fn"}8 (2%)0 (0%)Stent placement315 (86%)29 (59%)\<0.0001Coronary artery bypass graft surgery9 (2%)1 (2%)1.000Cardiogenic shock30 (8%)8 (16%)0.065Acute congestive heart failure18 (5%)8 (16%)0.002Cardiac arrest23 (6%)3 (6%)1.000Stroke1 (0.3%)1 (2%)0.223Death10 (3%)2 (4%)0.642Hospital length of stay (days)3 (2,4)3 (3,7)0.006Discharge status0.004 Home345 (95%)41 (84%) Rehabilitation8 (2%)5 (10%) Hospice2 (1%)1 (2%)[^4][^5]Table 4Univariable and multivariable logistic regression.Table 4Patient characteristicUnivariableMultivariableOR (95% CI)p-ValueOR (95% CI)p-ValueFemale sex2.3 (1.3--4.2)0.0072.0 (1.1--3.8)0.025Age (by decade)1.2 (1.0--1.5)0.099Diabetes mellitus3.7 (2.0--6.8)\<0.00013.4 (1.8--6.4)\<0.0001Prior myocardial infarction0.6 (0.2--1.3)0.195Prior heart failure2.2 (0.8--5.7)0.111Prior coronary artery bypass4.5 (1.4--14.0)0.010Absence of chest pain during presentation2.4 (1.2--4.7)0.0142.4 (1.2--4.8)0.016Chest pain in past 30 days0.6 (0.3--1.2)0.144[^6][^7]

Median follow-up for the entire cohort was 2.8 years (IQR 1.1--4.6). Survival was significantly lower in very late presenters at 1-year follow-up (73% vs. 93%, log-rank p ≤0.0001). A Kaplan-Meier survival curve showed increased long-term mortality in very late presenters (log-rank p = 0.007) ([Fig. 1](#f0005){ref-type="fig"}). Cox proportional hazard analysis calculated a hazard ratio of 2.3 (95% CI, 1.2--4.3, p = 0.009) for very late presenters compared to those presenting \<12 h.Fig. 1Kaplan-Meier time to event model for long-term mortality.Fig. 1

4. Discussion {#s0040}
=============

We found that 12% of STEMI patients presented very late (≤12 h) after symptom onset. Patients who presented very late were more likely to be women and diabetics, and were less likely to present with chest pain. We also found that patients who presented very late were less likely to call 911 and be transported by ambulance, suggesting they did not perceive their symptoms to be an emergency. Our results concur with prior reports focused on predictors of delayed presentation in STEMI \[[@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]\], and now extend to patients who present very late.

Longer total ischemic time has been associated with larger infarct size and increased mortality \[[@bb0035],[@bb0040]\]. In a recent study, STEMI patients with pre-hospital delays of ≥12 h had worse left ventricular systolic function and higher rates of acute heart failure \[[@bb0025]\]. Similarly, we found that very late presenters had more hemodynamic compromise with higher heart rates and lower blood pressures on presentation. During the index hospitalization, very late presenters were found to have higher initial troponin levels, worse left ventricular systolic function, and higher rates of acute heart failure compared to patients who presented earlier, indicating a sicker patient population.

Previous evidence has associated increased pre-hospital delay with increased in-hospital mortality \[[@bb0045]\]. While we did not find a difference in in-hospital mortality between the groups, long-term mortality was significantly higher in very late presenters. This was largely driven by increased death within the first 6 months. We contend that very late presenters remain at increased risk for death after hospital discharge and may benefit from increased post-discharge surveillance. Our results are different from a recent study of long-term mortality in STEMI patients which did not find increased mortality in those presenting late, however, in this study "late" was defined as \>60 min \[[@bb0030]\].

While prior studies have shown improved outcomes with revascularization in STEMI patients presenting between 12 and 48 h after symptom onset \[[@bb0050], [@bb0055], [@bb0060]\], current guidelines, partly based on the findings from the Occluded Artery Trial \[[@bb0065]\], recommend deferring reperfusion in patients presenting \>12 h who do not show evidence of ongoing ischemia \[[@bb0005]\]. Nevertheless, reperfusion with primary PCI \>12 h from symptom onset may attenuate the increased long-term mortality associated with very late presentation \[[@bb0055]\].

Despite significant reductions in door-to-balloon times through the mid-2000s \[[@bb0070],[@bb0075]\], more recently this trend has plateaued \[[@bb0080]\], suggesting little room for further improvement. Moreover, pre-hospital delay for at-risk populations have decreased marginally \[[@bb0010]\], underscoring potential improvement possibilities within this metric. Despite impressive advances in STEMI care, a sizable proportion of patients (12% in our study) continue to present very late and are subjected to longer total ischemic times. While prior efforts to reduce pre-hospital delay have been suboptimal \[[@bb0085]\], novel educational initiatives regarding STEMI symptoms (including lack of chest pain) and the importance of seeking medical attention early should continue with a special focus on vulnerable populations, including women and diabetics.

4.1. Study limitations {#s0045}
----------------------

Our study has several limitations. First, it was a retrospective study. Second, the population was predominantly white and our results may not be applicable to other patient populations. Third, symptom onset time was based on self-reported data which can be subject to recall bias. Fourth, we do not have information regarding the incidence of atrial fibrillation or mechanical complications of STEMI in our patient cohort.

5. Conclusions {#s0050}
==============

Female sex, diabetes, and absence of chest pain are strong predictors of presentation delay in STEMI, and long-term mortality is significantly increased in those presenting very late.
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[^1]: This author takes the responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

[^2]: Data presented as number (%), median (IQR).

[^3]: Data presented as number (%), median (IQR).

[^4]: Data presented as number (%), median (IQR).

[^5]: Other includes: Left Main, Ramus, and Internal Mammary Arterial graft.

[^6]: OR = odds ratio.

[^7]: CI = confidence interval.
